| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria João Bonifácio, P Nuno Palma, Luís Almeida, Patrício Soares-da-Silv. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS drug reviews. vol 13. issue 3. 2008-02-07. PMID:17894650. |
parkinson's disease (pd) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent reduction in striatal dopamine levels leading to characteristic motor symptoms. |
2008-02-07 |
2023-08-12 |
human |
| Oleg S Gorbatyuk, Shoudong Li, Layla F Sullivan, Weijun Chen, Galina Kondrikova, Fredric P Manfredsson, Ronald J Mandel, Nicholas Muzyczk. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 2. 2008-02-06. PMID:18178617. |
there was a significant reduction of dopaminergic neurons in the snc and dopamine (da) and tyrosine hydroxylase (th) levels in the striatum of all s129a-treated rats as early as 4 wk postinjection. |
2008-02-06 |
2023-08-12 |
human |
| Sunyoun Kim, Jungmin Nam, Kisok Ki. Aluminum exposure decreases dopamine D1 and D2 receptor expression in mouse brain. Human & experimental toxicology. vol 26. issue 9. 2008-01-31. PMID:17984145. |
the objective of this study was to determine the extent of expressional alterations in dopamine receptors (drs) in two dopaminergic subtypes, d1 and d2, in low and high dose al-treated mice. |
2008-01-31 |
2023-08-12 |
mouse |
| N P Podosinovikova, V V Petrov, V A Beliaev, A Ia Bespalov, V V Trefilov, V B Dolgo-Saburo. [Daphnia magna (straus): a new test object for modeling of dopaminergic neurotransmission deficiency induced by the selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine]. Eksperimental'naia i klinicheskaia farmakologiia. vol 70. issue 4. 2008-01-31. PMID:18078036. |
it is suggested to use d. magna as a simple and informative test object for the modeling of dopaminergic transmission deficiency and for the primary screening of various substances intended for the pharmacological correction of dopamine transmission disturbances. |
2008-01-31 |
2023-08-12 |
Not clear |
| R Mark Wightman, Michael L A V Heien, Kate M Wassum, Leslie A Sombers, Brandon J Aragona, Amina S Khan, Jennifer L Ariansen, Joseph F Cheer, Paul E M Phillips, Regina M Carell. Dopamine release is heterogeneous within microenvironments of the rat nucleus accumbens. The European journal of neuroscience. vol 26. issue 7. 2008-01-29. PMID:17868375. |
at other locations, transients were absent even though dopamine was available for release as shown by extracellular dopamine increases following electrical activation of dopaminergic neurons. |
2008-01-29 |
2023-08-12 |
rat |
| Aneta Tylec, Marta Stryjecka-Zimmer, Katarzyna Kucharska-Pietur. [Genetic polymorphism of COMT in mental disorders]. Psychiatria polska. vol 41. issue 4. 2008-01-29. PMID:18046978. |
many neurobiochemical studies show abnormalities within dopaminergic neuropathways, particularly altered dopamine transmission in etiopathogenesis of mental disorders. |
2008-01-29 |
2023-08-12 |
Not clear |
| Aneta Tylec, Marta Stryjecka-Zimmer, Katarzyna Kucharska-Pietur. [Genetic polymorphism of COMT in mental disorders]. Psychiatria polska. vol 41. issue 4. 2008-01-29. PMID:18046978. |
evaluation of genes associated with the dopaminergic system include five well known subtypes of dopaminergic receptors, dopamine transporter and enzymes associated with the synthesis and degradation of dopamine, such as tyrosine hydroxylase, dopa decarboxylase, monoamine oxidase (mao) and catechol o-methyltransferase (comt). |
2008-01-29 |
2023-08-12 |
Not clear |
| Dag Nyhol. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism & related disorders. vol 13 Suppl. 2008-01-25. PMID:17707679. |
in early pd, enough dopaminergic neurons remain to store dopamine provided by periodic dosing with oral levodopa and relatively normal, tonic levels of dopamine release are maintained. |
2008-01-25 |
2023-08-12 |
Not clear |
| Tiago B Rodrigues, Noelia Granado, Oskar Ortiz, Sebastián Cerdán, Rosario Moratall. Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. Journal of neuroscience research. vol 85. issue 15. 2008-01-22. PMID:17455302. |
metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through d(1) dopamine receptors. |
2008-01-22 |
2023-08-12 |
mouse |
| Tiago B Rodrigues, Noelia Granado, Oskar Ortiz, Sebastián Cerdán, Rosario Moratall. Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. Journal of neuroscience research. vol 85. issue 15. 2008-01-22. PMID:17455302. |
interactions between the dopaminergic and glutamatergic neurotransmission systems were investigated in the adult brain of wild-type (wt) and transgenic mice lacking the dopamine d(1) or d(2) receptor subtypes. |
2008-01-22 |
2023-08-12 |
mouse |
| Daniela Marazziti, Silvia Mandillo, Chiara Di Pietro, Elisabetta Golini, Rafaele Matteoni, Glauco P Tocchini-Valentin. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proceedings of the National Academy of Sciences of the United States of America. vol 104. issue 23. 2008-01-22. PMID:17519329. |
gpr37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. |
2008-01-22 |
2023-08-12 |
mouse |
| Maryka Quik, Heather Cox, Neeraja Parameswaran, Kathryn O'Leary, J William Langston, Donato Di Mont. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Annals of neurology. vol 62. issue 6. 2008-01-22. PMID:17960553. |
however, the cholinergic system has received little attention despite an extensive overlap between dopaminergic terminals and cholinergic interneurons in the striatum and the well-known ability of nicotine to stimulate striatal dopamine release. |
2008-01-22 |
2023-08-12 |
monkey |
| Annie Larouche, Patrick Berube, Philippe Sarret, Sylvain Grigno. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse (New York, N.Y.). vol 62. issue 1. 2008-01-22. PMID:17960767. |
little is known, however, on the effect of os on the regulation of the dopamine d2 receptor (drd2), a key component of striatal dopaminergic neurotransmission. |
2008-01-22 |
2023-08-12 |
Not clear |
| Helton J Reis, Daniela V F Rosa, Melissa M Guimarães, Bruno R Souza, Alexandre G A Barros, Flávio J Pimenta, Renan P Souza, Karen C L Torres, Marco A Romano-Silv. Is DARPP-32 a potential therapeutic target? Expert opinion on therapeutic targets. vol 11. issue 12. 2008-01-18. PMID:18020984. |
because of widespread interest in the dopaminergic pathways, the protein dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein with molecular weight of 32 kda, known by the acronym darpp-32, occupies a central role in the biology of dopaminoceptive neurons in the central and peripheral nervous system (pns). |
2008-01-18 |
2023-08-12 |
Not clear |
| Clement C Zai, Rudi W Hwang, Vincenzo De Luca, Daniel J Müller, Nicole King, Gwyneth C Zai, Gary Remington, Herbert Y Meltzer, Jeffrey A Lieberman, Steven G Potkin, James L Kenned. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The international journal of neuropsychopharmacology. vol 10. issue 5. 2008-01-17. PMID:16959057. |
abnormalities in dopaminergic activity in the nigrostriatal system have been most often suggested to be involved because the agents which cause td share in common potent antagonism of dopamine d2 receptors (drd2), that notably is not balanced by effects such as more potent serotonin (5-ht)2a antagonism. |
2008-01-17 |
2023-08-12 |
Not clear |
| Ana I Rojo, Carmen Cavada, María Rosa de Sagarra, Antonio Cuadrad. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Experimental neurology. vol 208. issue 1. 2008-01-17. PMID:17880941. |
these compounds displayed very different effects on motor activity, striatal dopamine and dihydroxyphenylacetic acid (dopac) levels and loss of dopaminergic neurons. |
2008-01-17 |
2023-08-12 |
mouse |
| Irmgard Paris, Sergio Cardenas, Jorge Lozano, Carolina Perez-Pastene, Rebecca Graumann, Alejandra Riveros, Pablo Caviedes, Juan Segura-Aguila. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease. Neurotoxicity research. vol 12. issue 2. 2008-01-17. PMID:17967736. |
aminochrome is an endogenous compound formed during dopamine oxidation and it is the precursor of neuromelanin, a substance whose formation is a normal process in mesencephalic dopaminergic neurons. |
2008-01-17 |
2023-08-12 |
Not clear |
| b' Tiina M K\\xc3\\xa4\\xc3\\xa4ri\\xc3\\xa4inen, Marko Lehtonen, Markus M Forsberg, Jouko Savolainen, Mikko K\\xc3\\xa4enm\\xc3\\xa4ki, Pekka T M\\xc3\\xa4nnist\\xc3\\xb. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic & clinical pharmacology & toxicology. vol 102. issue 1. 2008-01-17. PMID:17971064.' |
in the present study, we assessed the effect of single graded doses of a putative anxiolytic compound, the 5-ht(2a/c )antagonist, deramciclane fumarate (egis-3886), on the dopamine efflux and metabolism in nucleus accumbens and striatum and thus evaluated the dose window for deramciclane to cause adverse effects related to the brain dopaminergic system. |
2008-01-17 |
2023-08-12 |
rat |
| M D Neely, D E Schmidt, A Y Deutc. Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience. vol 149. issue 2. 2008-01-16. PMID:17888581. |
the striatal dopamine innervation was lesioned by treatment of the cultures with the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (mpp+) or by removing the mesencephalon. |
2008-01-16 |
2023-08-12 |
rat |
| Yajie Liang, Shurong Li, Qiang Guo, Yanling Zhang, Yanliang Zhang, Can Wen, Qiang Zou, Bingyin S. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain research. vol 1178. 2008-01-16. PMID:17900537. |
immunohistochemical staining of dopaminergic neurons in snpc and neurochemical analysis of dopamine and its metabolites in striata revealed that there was no significant difference between the two genotypes. |
2008-01-16 |
2023-08-12 |
mouse |